What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's biggest scorchers.
Research In Motion
Aurizon struck gold after receiving an unsolicited buyout offer. The gold producer, with projects in the Abitibi region of northwestern Quebec, announced on Friday that it formed a committee to explore the $792.6 million offer.
Pacific Biosciences of California continues to be one of the hottest stocks, up 76% so far this year and nearly tripling since bottoming out in November. There was no material news out on the DNA sequencing specialist this week, though momentum continues to linger since popping earlier this month, after a group including the FDA announced a new study based on Pacific Biosciences' technology.
Research In Motion continues to rally ahead of its Jan. 30 event for the big reveal of BlackBerry 10. There's a lot riding on the update to RIM's mobile operating system. As for news this past week, credit card issuing giant Visa approved RIM's mobile-payments solution.
Genworth Financial moved higher on a week where the news was largely mixed for financial companies. The wealth-management and financial-solutions provider moved on plans to separate its mortgage insurance business.
Opko Health hit a fresh 52-week high after its CEO continued his impressive string of share purchases. CEO Phillip Frost has now bought nearly $1.5 million worth of his company's stock this month. Opko also expanded its relationship with pharmaceuticals giant Bristol-Myers Squibb.
More winners for you
It was a great week for these five stocks, and now it's time to see which stocks will lead the way in the future. The Motley Fool's chief investment officer has selected his No. 1 stock for the next year. Find out which stock it is in our brand-new free report: "The Motley Fool's Top Stock for 2013." I invite you to take a copy, free for a limited time. Just click here to access the report and find out the name of this under-the-radar company.
The article 5 of Last Week's Biggest Winners originally appeared on Fool.com.
Longtime Fool contributor Rick Aristotle Munarriz has no position in any stocks mentioned. The Motley Fool recommends Pacific Biosciences of California and Visa. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.